


Amendments to the Claims

1. (Currently amended) A compound structurally represented by Formula I



(1)

or a pharmaceutically acceptable salts thereof wherein:

G¹ is -CH₂-, or -CH₂-CH₂-,

G² is -CH₂-, ~~or -C(O)-~~,

~~or G¹ and G² taken together combine to form -CH=CH- or -CH₂-CH=CH-~~,

Y is

-OCH₂CH₂N-piperidinyl, ~~or~~

-OCH₂CH₂CH₂N-piperidinyl,

~~-OCH₂CH₂N-pyrrolidinyl,~~

~~-OCH₂CH₂CH₂N-pyrrolidinyl,~~

X is H, -COR³, -CH₂R⁴, ~~or~~ -SO₂R⁵,

R³ is

-(C₁-C₈) alkyl, optionally substituted with 1 to 3 halogens,

-(C₃-C₈) cycloalkyl, optionally substituted with 1 to 3 halogens,

-O(C₁-C₈) alkyl, optionally substituted with 1 to 3 halogens,



, wherein R⁶ is -(C₁-C₆) alkyl, or -COO-(C₁-C₆) alkyl,

-Furanyl,

-Thienyl,

-NH-phenyl,

-NH-(C₁-C₄)alkyl-phenyl,

-NH-(C₁-C₈) alkyl, optionally substituted with 1 to 4 halogens,

-NH-(C₃-C₈) cycloalkyl, optionally substituted once or twice with halogens,
 -CH₂-pyridinyl,
 -CH₂N (C₁-C₆) alkyl (C₁-C₆) alkyl, or
 -CH₂N-phenyl,

R⁴ is

-(C₁-C₈) alkyl, optionally substituted with 1 to 4 halogens,
 -(C₃-C₈) cycloalkyl,
 -(C₁-C₈) alkyl-NH₂,
 -(C₁-C₄) alkyl -phenyl,
 -CH₂N-phenyl,
 -phenyl-O-(C₁-C₄) alkyl -phenyl,
 -(C₁-C₄) alkyl-O-(C₁-C₄) alkyl-phenyl,
 -CH₂NCO₂-(C₁-C₆) alkyl,
 -Phenyl,
 -Thienyl,
 -Furanyl,
 -Imidazolyl,
 -Naphthyl, or



, wherein R⁶ is -(C₁-C₆) alkyl, or -COO-(C₁-C₆) alkyl,

-biphenyl, and






R⁵ is







-Phenyl,
 -(C₁-C₄) alkyl, or
 -(C₁-C₄) alkyl -phenyl,

provided the compound is not 6-(2-Piperidin-1-yl-ethoxy)-2,3-dihydro-1H-indole.








2. (Currently amended) The compound of claim 1; wherein G¹ is -CH₂- R¹ and R² cyclize to form a 5-membered ring, or a pharmaceutically acceptable salt thereof.






3. (Currently amended) The compound of claim 1, wherein G^1 is $-\underline{\text{CH}_2-\text{CH}_2}-$, R^1 and R^2 cyclize to form a 6-membered ring, or a pharmaceutically acceptable salt thereof.
4. (Currently amended) The compound of claim 2 wherein Y is in the 5 position, or a pharmaceutically acceptable salt thereof.
5. (Currently amended) The compound of claim 3 wherein Y is in the 6 position, or a pharmaceutically acceptable salt thereof.
6. (Cancelled)
7. (Currently amended) The compound of claim 1, selected from the group consisting of:







Example Number	Structure
1	
2	
3	
4	
5	






6	
7	
8	
9	
10	
11	






12	 <chem>CC(C)(C)OC(=O)N1CCc2cc(OCCN3CCCCC3)ccc2C1Cl</chem>
13	 <chem>CC(C)(C)OC(=O)N1CCc2cc(OCCN3CCCCC3)ccc2C1Cl</chem>
14	 <chem>CC(C)(C)OC(=O)N1CCc2cc(OCCN3CCCCC3)ccc2C1Cl</chem>
15	 <chem>CC(C)(C)OC(=O)N1CCc2cc(OCCN3CCCCC3)ccc2C1Cl</chem>
16	 <chem>CC(C)(C)OC(=O)N1CCc2cc(OCCN3CCCCC3)ccc2C1Cl</chem>
17	 <chem>CC(C)(C)OC(=O)N1CCc2cc(OCCN3CCCCC3)ccc2C1Cl</chem>






18	
19	
20	
21	
22	
23	
24	






25	 <chem>C1CCN(C1)CCCOc2ccc3c(c2)C(CN3Cc4ccsc4)c5ccccc5</chem>
26	 <chem>C1CCN(C1)CCCOc2ccc3c(c2)C(CN3Cc4ccsc4)c5ccccc5</chem>
27	 <chem>C1CCN(C1)CCCOc2ccc3c(c2)C(CN3Cc4c5ccccc5cc4)c6ccccc6</chem>
28	 <chem>C1CCN(C1)CCCOc2ccc3c(c2)C(CN3Cc4ccccc4OCc5ccccc5)c6ccccc6</chem>
29	 <chem>C1CCN(C1)CCCOc2ccc3c(c2)C(CN3Cc4ccc(cc4)-c5ccccc5)c6ccccc6</chem>







30	 <chem>C1CCN(C1)CCCOc2ccc3c(c2)c(c[nH]3)Cn4ccoc4</chem>
31	 <chem>C1CCN(C1)CCCOc2ccc3c(c2)c(c[nH]3)CN(Cc4ccccc4)</chem>
32	 <chem>CCCCCN(Cc1ccc2c(c1)c(c[nH]2)C3CCN(C3)CCCO)c4ccccc4</chem>
33	 <chem>C1CCN(C1)CCCOc2ccc3c(c2)c(c[nH]3)CN(CCOc4ccccc4)</chem>
34	 <chem>C[C@H](Cc1ccccc1)N(Cc2ccc3c(c2)c(c[nH]3)C4CCN(C4)CCCO)c5ccccc5</chem>
35	 <chem>C[C@H](Cc1ccccc1)CN(Cc2ccc3c(c2)c(c[nH]3)C4CCN(C4)CCCO)c5ccccc5</chem>




36	 <chem>CCN1CCc2ccc(OCCCN3CCCCC3)cc21</chem>
37	 <chem>c1ccccc1CCCN2Cc3ccc(OCCCN4CCCCC4)cc32</chem>
38	 <chem>CC(C)(C)OC(=O)NCCN2Cc3ccc(OCCCN4CCCCC4)cc32</chem>
39	 <chem>CC(C)N1Cc2ccc(OCCCN3CCCCC3)cc21</chem>
40	 <chem>c1ccccc1S(=O)(=O)N2Cc3ccc(OCCCN4CCCCC4)cc32</chem>

41	
42	
43	
44	
45	

46	 <chem>O=C1C=Cc2cc(OCN3CCCCC3)ccc21C(=O)Nc4ccccc4</chem>
47	 <chem>O=C1C=Cc2cc(OCN3CCCCC3)ccc21C(=O)Nc4ccccc4</chem>
48	 <chem>O=C1C=Cc2cc(OCN3CCCCC3)ccc21C(=O)Nc4ccccc4</chem>
49	 <chem>O=C1C=Cc2cc(OCN3CCCCC3)ccc21C(=O)Nc4ccccc4</chem>
50	 <chem>O=C1C=Cc2cc(OCN3CCCCC3)ccc21C(=O)Nc4ccccc4</chem>

51	 Chiral
52	 Chiral
53	
54	
55	

56	
57	<p>Chiral</p> 
58	
59	<p>Chiral</p> 
60	<p>Chiral</p> 
61	

62	
63	
64	

or a pharmaceutically acceptable salt ~~or solvate~~ thereof.

8. (Previously presented) A pharmaceutical composition which comprises a compound of claims 1 or 7 and a pharmaceutically acceptable carrier.

9. (Cancelled)

10. (Cancelled)

11. (Cancelled)

12. (Cancelled)

13. (Cancelled)

14. (Cancelled)

15. (Cancelled)